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Abstract
Pancreatic Adenocarcinoma (PDAC), the fourth highest cause of cancer related deaths in the United States, has the most
aggressive presentation resulting in a very short median survival time for the affected patients. Early detection of PDAC is
confounded by lack of specific markers that has motivated the use of high throughput molecular approaches to delineate
potential biomarkers. To pursue identification of a distinct marker, this study profiled the secretory proteome in 16 PDAC, 2
carcinoma in situ (CIS) and 7 benign patients using label-free mass spectrometry coupled to 1D-SDS-PAGE and Strong
Cation-Exchange Chromatography (SCX). A total of 431 proteins were detected of which 56 were found to be significantly
elevated in PDAC. Included in this differential set were Parkinson disease autosomal recessive, early onset 7 (PARK 7) and
Alpha Synuclein (aSyn), both of which are known to be pathognomonic to Parkinson’s disease as well as metabolic enzymes
like Purine Nucleoside Phosphorylase (NP) which has been exploited as therapeutic target in cancers. Tissue Microarray
analysis confirmed higher expression of aSyn and NP in ductal epithelia of pancreatic tumors compared to benign ducts.
Furthermore, extent of both aSyn and NP staining positively correlated with tumor stage and perineural invasion while their
intensity of staining correlated with the existence of metastatic lesions in the PDAC tissues. From the biomarker perspective,
NP protein levels were higher in PDAC sera and furthermore serum levels of its downstream metabolites guanosine and
adenosine were able to distinguish PDAC from benign in an unsupervised hierarchical classification model. Overall, this
study for the first time describes elevated levels of aSyn in PDAC as well as highlights the potential of evaluating NP protein
expression and levels of its downstream metabolites to develop a multiplex panel for non-invasive detection of PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer death in USA and has one the lowest survival rates
for solid cancers [1]. Most patients diagnosed with pancreatic
cancer die within 12 months, and only 4% survive 5 years after
diagnosis. This is largely due to late presentation by affected
patients, thereby making therapeutic intervention difficult [2].
Early diagnosis of pancreatic cancer, including pre-neoplastic
lesions (designated as pancreatic intraepithelial neoplasia or
PanIN) in average-risk and high-risk patients is desperately needed
to improve the survival rate of pancreatic cancer patients [3,4,5].
Carbohydrate antigen 19-9 (CA 19-9), also known as sialylated
Lewis (a) antigen is the only reliable and widely used biomarker for
diagnosis of pancreatic cancer (sensitivity 70%, specificity 87%)
[6,7]; however, its use is largely limited to following the course of
disease [8,9]. It must be noted that CA19-9 is not specific for
pancreatic cancer alone, as it is expressed in some other cancers
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cholangitis and chronic pancreatitis [10,11,12,13]. Recently,
several approaches have been used to find candidate biomarker
for pancreatic cancer to facilitate early diagnosis including
microarrays and proteomics [14,15,16,17,18,19,20,21,22,23].
Proteomic profiling for pancreatic cancer biomarker discovery is
still at its early stage; however, the efforts so far have been
productive and the results are encouraging [15,16,18,19,21,22,24].
Proteins by virtue of being the functional denominators of cellular
phenotype have garnered a lot of attention as potential biomarkers
in cancer. Most of the proteomics approaches for PDAC have
focused on assessment of tissue proteome [25,26,27] and to some
extent examination of proteins secreted in the pancreatic juice
[18,22,23,28]. The latter constitutes a rich source of cancer-
specific proteome contributed by cellular turnover and degrada-
tion of highly proliferative cancer cells that are shed into the juice.
This has motivated multiple groups to profile the pancreatic juice
proteome using both qualitative and quantitative mass spectrom-
etry. These include Surface-Enhanced Laser Desorption/Ioniza-
tion Time-Of-Flight Mass Spectrometry (SELDI TOF MS) [29],
qualitative 2-Dimensional Electrophoresis (2DE)-based mass
spectrometry [30] and quantitative Isotope-Coded Affinity Tags
(ICAT)-labeled mass spectrometry [18]. Each of these has
identified subsets of proteins that are altered in pancreatic cancer
compared to non-cancer controls. However, in addition to being
limited by the number of patient samples analyzed, none of the
secretory proteins identified have been developed further into a
clinically testable biomarker format. Here, we report mass
spectrometry based proteomic profiling of pancreatic juice
specimens from 25 patients (7 benign, 2 carcinoma in situ (CIS)
and 16 pancreatic adenocarcinoma or PDAC). The profiling data
revealed a set of 56 proteins that were elevated in PDAC patients
compared to benign controls (patients diagnosed with pancreatitis,
adenoma etc). Among the candidates identified, were proteins
previously reported to be elevated in PDAC namely Mucin 1[22],
alpha-glycoprotein [31], alpha1-antitrypsin [32], isoforms of 14-3-
3 protein, S-100 [33], PARK 7 (autosomal recessive, early onset 7)
[34,35,36] etc, as well as new ones. The latter included Alpha-
Synuclein (aSyn) and metabolic enzymes like Purine Nucleoside
Phosphorylase (NP), both of which were elevated in pancreatic
juice from patients with PDAC compared to benign controls.
Interestingly both aSyn and PARK 7 are known to be
pathognomonic to Parkinson’s disease (PD) [34,35,37,38,39].
Further, independent tissue microarray validation for the first
time revealed aggregation of aSyn in a subset of PDAC specimens,
similar to its presentation in PD. This suggests existence of a novel
and thus far unexplored biological mechanism for the develop-
ment of PDAC, with semblance to PD. Also higher expression of
NP coupled to elevated levels of its down-stream metabolites, in
serum had the potential to distinguish PDAC patients from benign
controls, highlighting their biomarker potential.
Results
Figure 1 outlines the strategy employed in this study. In brief,
we performed mass spectrometry-based proteome profiling of
pancreas-derived juice (n=25 consisting of 7 benign, 2 CIS, and
16 PDAC juice specimens). Trypsin-digested, fractionated pep-
tides from each clinical specimen were independently identified
and quantified using a MudPIT approach using HPLC-Chip nano
ESI-MS/MS analysis. The data was normalized on a per sample
basis and list of proteins derived from each sample was used to
generate a list of pancreas-associated proteome. The proteome was
then interrogated for class-specific expression signatures, a subset
of which were validated using immunoblot and tissue microarray
analysis (TMA) in independent tissues and serum specimens.
Furthermore, metabolite levels for NP- regulated metabolites were
also examined in pancreas-derived serum specimens. Importantly,
our data suggests existence of a Parkinson’s disease protein
signature in PDAC and describes the combined ability of Purine
Nucleoside Phosphorylase protein and its regulated metabolites in
serum to distinguish PDAC patients from benign individuals.
Quantitative Assessment of Pancreatic Juice Proteome
Using MudPIT proteomic profiling approach 431 proteins were
identified with a false discovery rate (FDR) of 1% (Figure S1 for
heat map); 84% (362) of them were identified in common
between benign and PDAC specimens. The total number of
spectra from either benign or PDAC specimen were independently
normalized, and the normalized cumulative spectral counts of all
the peptides for each protein were used as a measure of protein
abundance. Based on the statistical analysis of data involving two-
sided t-test coupled to FDR (false discovery rate) correction [40],
proteins were designated as differentially expressed either in the
PDAC (up-regulated) or benign (down-regulated) specimens (see
[Methods] section, for details). As shown in Figure 2A a total of
56 proteins were found to be significantly (P#0.05, FDR#12%)
up-regulated in pancreatic juice from PDAC patients compared to
benign. Included in these were proteins reported earlier to be
associated with PDAC as well as additional ones that were found
to be elevated in PDAC for the first time in this study. The latter
included Alpha-Synuclein (aSyn) that is known to be associated
with Parkinson’s Disease [37,38,39], as well as proteins like Purine
Nucleoside Phosphorylase (NP), Valosin Containing Protein
(VCP), Thrombospondin-1(THBS1) etc, all of which were found
to be elevated in PDAC-derived juice specimens.
Interrogation of SNCA, PARK-7 and NP in PDAC tissues
aSyn has been known to be an integral component of Lewy
body that are characteristic of Parkinson’s disease [37]. Further
PARK-7 a.k.a. DJ-1 has also been known to be associated with
Parkinson’s disease and earlier shown to be elevated in pancreatic
juice in PDAC patients [31]. However, aSyn overexpression in
PDAC has not been reported thus far. We confirmed our profiling
data on pancreatic cancer-associated aSyn and PARK 7
overexpression using a combination of TMA and immunoblot
analysis performed on tissue specimens from PDAC patients and
benign individuals. Figures 2B and S2 validates the elevated
expression of PARK-7 in PDAC tissues compared to benign
controls. Immunohistochemical staining for PARK-7 (Figure. S2)
revealed a heterogeneous pattern of staining of both cytoplasm
and nuclei. To correlate PARK-7 expression with various clinical
parameters, the staining pattern of the protein in the TMA’s were
scored both for the intensity and extent by two independent
pathologists. The scores for the two parameters were then
combined to generate an overall cumulative score which was
categorized as weak (0–3), moderate (4–5) or strong (.5). As
quantified in Figure S2C, about 80% of the PDAC specimens
(n=76) showed strong staining for PARK-7 compared to 65% of
the benign tissues (n=28). Further examination revealed that only
1/28 benign specimens had a strong focal staining (intensity score:
3+) compared to 22/76 PDAC tissues that show such a pattern.
Evaluation of staining in the other components including stroma,
islets and acini were not performed. Similar validation of aSyn
expression in pancreas derived tissues (n=78) was performed by
TMA. Figure 2 (C–E) shows a representative photomicrograph
of aSyn staining in a benign (panel C) and PDAC specimen (panels
D and E). Intense staining for aSyn was seen in epithelial cells of
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Figure S3 for additional photomicrographs of aSyn staining). The
staining predominantly exhibited a cytoplasmic distribution with
focal peri-apical prominence. Interestingly, in a few of the PDAC
tissues wherein the tumor had advanced to a metastatic stage,
aSyn expression displayed an aggregated appearance as seen in
Parkinson’s disease [37] (Figure 2E, refer Figure S4 for
additional photomicrographs showing aggregated appearance of
aSyn in metastatic PDAC). A semi-quantitative scoring of the
TMA as described earlier revealed weak to moderate staining for
aSyn in majority (,92%) of the benign specimens (n=25) while a
large proportion of (,84%) of the PDAC specimens (n=70)
exhibited moderate to strong staining patterns (Figure 2F).
Furthermore, the extent of aSyn staining was positively correlated
Figure 1. Workflow for Proteomic Profiling of Pancreatic Juice Proteome. Pancreatic juice specimens from 25 patients (7 benign and 18
PDAC) were collected in tubes containing protease inhibitors. The proteome was subjected to pre-fractionation using either SDS-PAGE or SCX-
fractionation. For 1D-SDS-PAGE based fractionation, 100 mg of pancreatic juice proteome was electrophoresed on a 8–16% SDS-PAGE and the gel
was excised into 30 equal pieces and subjected to in-gel trypsin digestion as described in the methods section. For SCX fractionation, 200 mgo f
pancreatic juice proteome was first subjected to in-solution trypsin digestion followed by separation of peptides into 20 fractions. Peptides derived
from both these methods were separated using reverse phase chromatography on a 43 mm HPLC-Chip and analyzed using an Agilent XCT-ultra ion
trap or 6510 QTOF mass spectrometer. The raw spectral files were converted into mzXML format and searched with X!Tandem using a Human IPI-
database (see methods for details). The identified peptides and proteins were curated using PeptideProphet and ProteinProphet and the class-
specific protein signatures were obtained using coupled to t-test and FDR correction (see methods for details). A subset of PDAC-associated proteins
and NP were examined by tissue microarrays and immunblot analysis to confirm their PDAC-specific overexpression in tissues, while expression of NP
and its downstream metabolites were examined in serum specimens using immunoblot analysis and targeted LC-MS respectively.
doi:10.1371/journal.pone.0017177.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17177Figure 2. Over view of pancreatic juice proteome and validation of PARK-7 and SNCA expression in PDAC and benign tissues.
A, Heat map representation of the 56 significantly altered proteins (P,0.05 & FDR,12%) in 25 pancreatic juice specimens (7 benign, 2 CIS and 16
PDAC). Columns represent samples and rows refer to proteins. Shades of yellow represent elevated expression of the protein and shades of blue
indicate decrease in the protein levels relative to its median expression value (see color scale). B, immunoblot confirmation of elevated PARK-7 (DJ-1)
expression in PDAC tissues. C, representative photomicrograph of the TMA showing immunostaining of aSyn in benign pancreas D, same as C but in
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(p=0.018 and 0.0019, respectively, one-sided Spearman’s corre-
lation) while it was negatively correlated to the presence of
metastatic lesions in the patient (p=0.0003, Table S1).
Importantly, the finding of an association for both aSyn and
PARK-7 in PDAC progression as revealed in this study suggests a
possible nuance in the etiology of pancreatic cancer and
Parkinson’s disease that needs further interrogation.
In addition to the above finding, we also examined the
association of NP with PDAC in greater detail as the activity of
this enzyme, a critical component of salvage metabolism of
purines, is extensively used by tumors to replenish their nucleotide
pools. Importantly, as shown in Figure 2A, NP levels were higher
in PDAC-associated juice compared to benign controls. The
higher levels of this protein in PDAC combined with the earlier
report on elevated NP activity in cancers [41], motivated us to
evaluate this protein in PDAC tissues. As shown in Figure 3A,
immunoblot analysis confirmed elevated expression of NP in
PDAC tissues compared to benign specimens. This was further
confirmed using TMA analysis on 67 PDAC and 26 benign
samples. NP staining on the TMA was categorized as weak,
moderate or strong as described earlier for PARK-7 and aSyn. As
shown in Figure 3B and quantified in Figure 3D, all the benign
specimens (n=26) showed weak (,77%) to moderate (,19%)
staining for NP while majority of the PDAC specimens (n=67)
exhibited a strong staining pattern (,79%) for the protein
(Figure 3C, D). This strong association of NP with PDAC tissue
combined with its secretory nature (Figure 2A) prompted us to
examine the protein levels for NP in serum of PDAC and control
individuals. As shown in Figure 3E, immunoblot analysis for NP
in serum revealed two bands at ,32 KDa. Of these the upper
band was predominantly seen in PDAC specimens and low to
undetectable in majority of the benign sera (Figure 3E). When
quantified relative to IgM (loading control), the normalized
intensity for upper immunoreactive band for NP was found to
be significantly elevated in PDAC sera (n=35, p,0.01, two-sided
t-test using log-transformed data) compared to benign controls
(n=20, Figure 3F), while it was undetectable in a subset of sera
from other tumor types (Figure S5). This predominance of NP
expression in PDAC sera supported by an earlier report on its
elevated enzyme activity in cancers [41] alluded to the possibility
of finding altered levels of its target metabolites in serum of PDAC
patients. Accordingly, levels of 7 metabolites namely adenine,
adenosine, guanine, guanosine, xanthine, hypoxanthine and
inosine which are either substrates or products of NP were
measured in PDAC and benign sera using targeted LC-MS/MS.
Serum levels of each of these metabolites were reported as a ratio
to levels of labeled thymine (D4-thymine), an internal standard
spiked at equimolar levels into each of the serum sample prior to
metabolite extraction. The mass spectral data was pre-processed as
described in the [methods] section and the normalized ratio of the
metabolites to the internal standard were used to classify the serum
samples using unsupervised hierarchical clustering. As shown in
Figure 3G, the 48 serum samples (24 Benign, 24 PDAC) used in
the analysis were delineated into three major clusters based on the
relative levels for the 7 metabolites examined, and these
significantly demarcated the two sample classes (Figure 3G,
p=0.00025, one-sided Fisher’s exact test). Specifically, 22/24
PDAC specimens were grouped into clusters 1 and 3 respectively
while 14/24 benign specimens were grouped in cluster 2
(Figure 3G). Furthermore, levels of adenosine and guanosine
independently correlated with the PDAC status (p,0.04, two-
sided t-test).
Discussion
The treatment of pancreatic adenocarcinoma remains a clinical
challenge. The majority of patients are diagnosed at an advanced
stage beyond what current therapy can benefit. Most patients have
a vague prodrome of symptoms prior to diagnosis making early
detection difficult and therefore uncommon [42]. Currently no
clinically useful interventions to screen for patients with PDAC are
available. The purpose of this project was to evaluate the protein
expression profiles of pancreatic juice samples harvested from the
pancreatic duct at the time of surgery to potentially identify unique
markers that could be used to differentiate benign from malignant
pancreatic masses and further delineate different grades of PDAC.
65 proteins were specifically seen only in adenocarcinomas and 4
proteins were observed solely in the benign pancreatic masses.
Further, a total of 56 proteins were elevated in pancreatic juice of
PDAC compared to benign controls. Of interest, these differen-
tiating profiles revealed the unique presence of proteins associated
with Parkinson’s disease namely: aSyn and PARK7
[34,35,37,38,39]. The presence of aSyn in PDAC has not been
reported in the literature and previous mouse/drosophila models
for this protein have not reported alterations in pancreas function
or incidence of pancreatic cancer [43,44,45]. However, elevated
expression of aSyn has been recently reported in melanoma [46],
while its isoform gamma-synuclein (cSyn) a.k.a. Breast Cancer
Specific Protein-1 has been shown to be elevated in tumors of
breast, uterine, colorectal and pancreas [47,48,49,50,51,52,53,54].
Further, cSyn that has 63% identity to aSyn at the protein level,
has been reported to potentiate invasion in these tumors
[49,50,51,53]. In light of this, it was interesting to observe higher
levels of aSyn in PDAC. Specifically our tissue arrays demonstrate
strong staining for aSyn in tumors compared to moderate to weak
staining for benign masses. Of further interest, this protein
expressed in a subset of PDAC patients was identified in its
aggregated form. This aggregation is characteristic of Lewy Bodies
seen in Parkinson’s disease which is thought to contribute to the
degenerative disease process [37,55]. Similarly, elevated levels of
an additional Parkinson’s disease associated protein PARK7 (DJ1)
[34], in pancreatic ductal juice of adenocarcinomas corroborate an
earlier report [31]. Also other studies have documented DJ-1 over-
expression to be associated with moderately differentiated PDAC
[56]. Furthermore, DJ-1 has been reported to protect neuronal
cells from apoptosis [57,58] while function as an oncogene in
tumor cells [59,60]. However, the exact mechanism by which
PARK-7 exerts its oncogenic effect is not clearly understood,
although it is presumed to involve p38 mitogen activated-protein
kinase signaling [60]. These results are indicative of a link between
PDAC and neurodegenerative disease like Parkinson’s disease that
will need to be further investigated.
In addition to the above findings, the PDAC-associated
secretory proteome also revealed elevated levels of a number of
additional metabolic enzymes. One of these was Purine Nucleo-
side Phosphorylase (NP), the rate limiting enzyme in salvage
pathway involving purines, which is operational during inflam-
mation as well as neoplastic progression, and has been highly
targeted by various chemotherapeutic agents [61,62,63]. In
PDAC E, Higher magnification of D showing aggregated staining pattern for aSyn in PDAC F, quantification of TMA staining for aSyn in benign
(n=11) and PDAC samples (n=67). Magnification of A and B: 40X, for C: 100X.
doi:10.1371/journal.pone.0017177.g002
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cancer sera [41]. NP expression has also been used to determine
the clinical severity of various types of leukemias and lymphomas
especially as a ratio to adenosine deaminase (ADA)[64]. Likewise
in the area of inflammation, NP deficiency has been reported in
immune deficient syndromes, like severe combined immunodefi-
ciency syndrome (SCID) [65,66,67]. This strong association of NP
with inflammation and its earlier use in assessing severity of
leukemia/lymphoma motivated us to evaluate the expression and
activity of this protein in PDAC, specifically in patients with
antecedent inflammatory conditions like chronic pancreatitis.
Furthermore, previous investigations have correlated chronic
pancreatitis and the development of pancreatic intraepithelial
neoplasia (PanIN) [68]. Thus there are strong correlates to suggest
that antecedent chronic inflammation could be a known factor to
develop PanIN or PDAC and NP may be a useful marker to
monitor the progression from inflammation to PDAC.
Importantly, no previous studies have considered measuring
expression of NP protein or its regulated metabolites in PDAC. Our
results on NP protein levels in sera show the presence of two bands
at ,32 KDa predominantly in PDAC sera compared to controls.
Among these, we presume the differential upper band seen in
PDAC sera could represent the phosphorylated form of the protein.
Although this needs to be validated in PDAC, NP phosphorylation
has been earlier reported in neuronal cells exposed to oxidative
stress [69]. Further, in a proof-of-concept setting, our results also
show alterations in levels of metabolic intermediates downstream of
NP, in PDAC sera, alluding to the existence of an active NP-driven
purine salvage pathway in these tumors. This could be an adaptive
mechanism developed by PDAC to elude the toxicity of
chemotherapeutics as well as the cytotoxic effects of the chronic
andintenseinflammatorycascade oftenassociatedwiththetumor;a
hypothesis that needs further investigation. Importantly, from a
biomarker development perspective, these findings will need to be
validated in larger cohort of independent clinical specimens.
Furthermore, it will be interesting to focus future investigations on
evaluating the potential of NP to predict PDAC’s with antecedent
chronic pancreatitis and the influence on the development of
PanINs in the inflammatory milieu.
In summary, the study describes the secretory proteomic profiles
for PDAC which reveals a Parkinson’s signature suggestive of a
possible nuance between pancreatic tumors and the neurodegen-
erative disorder. Furthermore, the secretory profiles reveal NP to be
elevated in PDAC, indicative of a reliance of the tumor on the
salvage pathway. Importantly, levels of NP-regulated metabolites in
serum were able to distinguish PDAC from benign patients
highlighting its potential for future biomarker development. This
finding sets the stage to evaluate NP as a possible marker to predict
PDAC with antecedent pancreatitis, a clinical challenge that
currently has no predictive markers.
Materials and Methods
Subjects and Samples
The study was performed with approval from the Office of
Human Research Protection/Institutional Review Board (IRB) of
the Scott and White Memorial Hospital, Texas and Medical
College of Georgia, Augusta. Written informed consent was
obtained from all study subjects. Pancreatic juice specimens were
obtained from volunteering PDAC/CIS patients (n=18) or non-
cancer controls (n=7) undergoing surgical resection of pancreas at
Scott and White Memorial Hospital, Texas and Medical College
of Georgia Hospital, Augusta, GA. The pancreatic juice samples
were collected in tubes containing protease inhibitors and were
immediately frozen until further analyses. Detailed clinical and
pathology data for this study are available in Table S2. For the
validation studies tissue microarray consisting of 104 pancreas-
derived tissues (n=28 benign, and 76 PDAC, see Table S3 for
clinical information) were used. These specimens were obtained
from Scott and White Memorial Hospital (n=28), Texas and
Medical University of South Carolina (Charleston, SC, n=50),
with approval from the Office of Human Research Protection/
Institutional Review Board (IRB) of the respective institutions.
Additionally 59 serum samples from 24 PDAC, 23 benign, and 11
cancers of non-pancreatic origin were obtained upon IRB
approval from Scott and White Memorial Hospital, Texas and
Medical College of Georgia, Augusta and used for biomarker
evaluation studies (See Table S4).
Pancreatic juice proteomics using 1D gel protein
separation and in-gel digestion
Simple protein separation by 1D-SDS-PAGE before LC-MS/
MS (1D-gel-LC-MS/MS) minimizes the sample loss in general,
and captures proteins with a wide range of biochemical
characteristics (size, extremes of pI, transmembrane domains,
PTM’s etc) [70,71,72,73]. Pancreatic juice sample recovered from
patients with pancreatic cancer and/or pancreatitis/benign tumor
(control), containing 100 mg of total protein, were mixed with
sample buffer, boiled for 5 min and then separated on 8–16%
acrylamide gradient gels (Life-Gels). After staining with Simply-
Blue SafeStain (Invitrogen), the individual gel lanes were cut into
30 equal slices using Bio-rad exquest spot cutter. Gel pieces were
then subjected to in-gel digestion with trypsin in ammonium
bicarbonate (NH4HCO3) buffer, and peptides extracted as
described earlier by Shevchenko et al. [74], with a few minor
modifications [75]. Peptides were sequentially extracted in 20 mL
20% formic acid, 100 mL5 0 m MN H 4HCO3 and 0.1%
trifluoroacetic acid (TFA) in H2O:acetonitrile (1:1) mixture by
sonication for 5 min. The extracted peptides were then concen-
trated in a SpeedVac to ,10 mL, cleaned and desalted with C18
zip-tips. These desalted peptides were completely dried in a
SpeedVac and redissolved in 10 mL of 0.1% TFA for LC-MS/MS
analysis.
Fractionation of pancreatic juice proteome using Cation-
Exchange Chromatography (SCX)
Pancreatic juice proteins (200 mg) recovered from patients with
pancreatic cancer and/or pancreatitis/benign tumor (controls) was
first subjected to in-solution double trypsin digestion as described
earlier [76,77]. The resulting peptide mixtures were completely
dried in a SpeedVac and resuspended in 40 mL of 0.1% Formic
Figure 3. Validation of elevated expression of Nucleoside Phosphorylase (NP) and levels of its regulated metabolites in PDAC. A,
Immunoblot confirmation of elevated NP expression in PDAC tissues. B, representative photomicrograph of the TMA showing immunostaining of NP
in benign pancreas C, same as B but in PDAC D, quantification of TMA staining for NP in benign (n=11) and PDAC samples (n=49). Magnification of
B and C: 40X E, immunoblot showing predominant expression of a doublet at ,32 KDa immunoreactive to NP antibody in PDAC sera. +control:
10 mg total protein from PANC-1 F, immunoblot-based quantification of NP levels in benign and PDAC sera G, Unsupervised hierarchical classification
of PDAC (n=24) and benign (n=24) specimens based on the relative levels of 7 NP regulated metabolites in serum. Columns, samples; rows,
metabolites. Asterisks denote metabolites individually correlated (P,0.05, t-test) with PDAC/benign status.
doi:10.1371/journal.pone.0017177.g003
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16150-mm Poly-SEA strong cation exchange column (Michrom
Bioresources, Auburn, CA) using Agilent 1200 auto sampler.
Buffer containing 1 M ammonium formate, 10% Formic acid in
5% acetonitrile (mobile phase B) was used to create a linear
chromatographic gradient at a flow rate of 50 mL/min. A total of
10 fractions were collected over a 40 min gradient encompassing a
salt concentration of 0–100 mM ammonium formate. Additional 5
fractions were generated over the next 10 minutes at higher salt
concentration range of 100–1000 mM. Fractionated peptides were
completely dried and reconstituted in 10 ml of 0.1% TFA prior to
LC-MS/MS analysis.
HPLC-Chip-MS/MS analysis
For mass spectrometry analysis, approximately 10% of peptide
fraction was injected into a 1100 Series HPLC-Chip Cube MS
interface, and Agilent 6300 Series Ion Trap (XCT ultra) or 6510
QTOF Chip-LC-MS/MS system (all Agilent Technologies). The
system is equipped with a HPLC-Chip (Agilent Technologies) that
incorporates a 40 nL enrichment column and a 43 mm675 mm
analytical column packed with Zorbax 300SB-C18 5 mm particles.
Peptides were loaded onto the enrichment column with 97%
solvent A (water with 0.1% formic acid) and 3% solvent B
(acetonitrile with 0.1% formic acid) at a flow rate of 4 mL/min.
Peptides were then eluted with a gradient 3% to 45% B in 25 min,
followed by a steep gradient to 80% B in 5 min at a flow rate of
0.3 mL/min. The total run time, including column reconditioning,
was 35 min. MS/MS data was collected as described earlier [76]
with minor modification in collision energy for QTOF (slope of
3.7 V/100 Da and offset of 2.5 V). The CID data was analyzed as
described below.
Mass Spectral Data Analysis
MS/MS spectra generated above were extracted from the raw
data in mzXML file format using a converter from the Institute for
Systems Biology (http://tools.proteomecenter.org/wiki/index.
php?title=Software:trapper). The mzXML files were searched
using X! Tandem against the Human IPI database version 3.50
(containing 67,665 entries) appended with an equal number of
decoy sequences (reversed sequences from the original database).
The following search parameters were used to search the spectral
files against the database: Tandem/k-score database search,
tryptic peptides only, not more than 1 missed cleavage, C+57 as
fixed and M+16 as variable modifications respectively and 0.8 Da
set as the precursor mass tolerance. In total, 11,297,594 (mostly
doubly charged and triply charged) X! Tandem search results were
obtained. The search results were further processed using the
Trans-Proteomic Pipeline (TPP, www.proteomecenter.org), which
includes the PeptideProphet and ProteinProphet tools for peptide
and protein-level analysis using default settings. The data set was
filtered to keep only proteins identified with a FDR of 1%,
resulting in a total of 431 proteins. These were referenced by
International Protein Index (IPI) number (http://www.ebi.ac.uk/
IPI/IPIhelp.html). Gene Symbol information for the IPI numbers
was taken from the EMBL-EBI database for human IPI numbers
using http://www.ebi.ac.uk/IPI/IPIhuman.html on March 7,
2008.
MudPIT analysis
The proteins identified in each sample were grouped and used
to generate a composite list for all samples examined in this study.
An in-house software was used to resolve ambiguities resulting
from protein isoforms and multiple accession numbers [78]. At the
beginning, for each protein (or protein group with multiple
accession numbers) in the combined lists, the total number of MS/
MS spectra that were assigned a peptide mapping to that protein
was calculated. Following this, the spectrum count measures for
each protein were normalized. Normalization was done to account
for small differences in the number of identified peptides across
experiments. It was taken as the total number of spectra observed
in each experiment that were assigned a peptide from a protein
identified in the experiment with high probability. For proteins
that were identified in both experiments, the ratio of normalized
spectrum counts was calculated and then log-transformed. The
resulting distribution was determined using a robust Gaussian
distribution fitting procedure with outlier removal (10% of the
data), following which the mean and standard deviation (SD) were
calculated. Based on the statistical analysis of data involving two-
sided t-test coupled to FDR (false discovery rate) correction,
proteins were designated either as being up-regulated in PDAC or
benign specimens.
Heat map Plots
Heat maps of proteomic data were drawn using the image
function in software R [79]. Heat map in Figure 2 A, represents
unsupervised hierarchical clustering of the data (rows) grouped by
sample type (columns) based on Euclidean distance. Shades of
yellow and blue represent an increase and decrease in protein
expression respectively relative to the median protein expression
calculated post-log transformation and normalization of the data
of log-transformed normalized protein levels (see color scale in
Figure 2A).
For the heat map in Figure 3 G, the color coding was derived
using the ranking of the log ratio in the distribution of measures for
that sample, the intensity of the color being determined by the
distance (in standard deviations) from the mean of the distribution.
Cluster heat maps (average linkage method) of metabolite data
were generated using Cluster.exe and Java Treeview [80,81],
using the log ratios of metabolite versus D4-thymine (internal
standard, IS), centered on the median across samples.
Immunoblot Analysis
Proteins for immunoblotting were resolved by 4–12% NU-
PAGE gels (Invitrogen) and transferred to PVDF membranes (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ). The membranes
were blocked for 1 hr with 3% skimmed milk in TBS-T (20 mM
Tris.HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20). Antibodies
specific NP-1 and PARK-7 (both monoclonal from Abcam,
Cambridge, MA) were added in TBS-T containing 3% skimmed
milk and incubated overnight. Antibodies specific to Glyceralde-
hyde-3-Phosphate Dehydrogenase (GAPDH, Santa Cruz Biotech-
nology, Santa Cruz, CA) were used to ensure equal protein
loading since levels of beta-actin were found to be altered in the
pancreatic tissues. The blots were subsequently washed with
TBST and incubated with respective secondary antibodies. For
LICOR experiments, seablock blocking buffer (ThermoScientific,
Rockford, IL) was used instead of 3% skimmed milk. Immunoblot
signals were developed using either ECL or ECL-plus chemilu-
minescence reagent (for tissues, GE Healthcare Bio-Sciences
Corp., Piscataway, NJ) or using LICOR for sera. Horse-radish
peroxidase labeled or fluorescent labeled antibodies were used for
ECL and LICOR (Lincoln, NE) experiments respectively. In
experiments involving evaluation of NP levels in serum, 10 mgo f
total protein from PANC-1 cell line was used in each blot as an
internal reference (or + control).
Immunoblot data for NP in PDAC and control serum was
quantified using IMAGE J software (http://rsbweb.nih.gov/ij/).
Specifically, for each serum the intensity of the upper band for NP
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ratio of the intensities of the two bands was calculated and
represented (as %) relative to the intensity of NP in the internal
reference standard (PANC-1).
Tissue Microarrays
A total of 104 paraffin embedded tissues that included 28
benign pancreas and 76 PDAC were used to construct the tissue
microarrays (TMA). TMA’s were constructed from representative
3.0 mm cores of tissue (verified by 2 independent pathologists)
from cases of adenocarcinomas and pancreatitis. The cores were
constructed using a Tissue-Tek Quic-Ray (Sakura, CA) technique
and inserted into a pre-formed block, sectioned at 4 micron
thickness and subjected to immunohistochemistry. Epitope
retrieval was achieved by steam-heating the tissue slides for 20
minutes in high pH (EnVision FLEX Target Retrieval Solution,
high pH, DAKO, Carpinteria, CA). Following a 20 minute
cooling, the tissue sections were incubated with a 1:200 dilution of
a monoclonal antibody to aSyn from BD Biosciences (San Jose,
CA) for 20 minutes. The detection system used was the
ENVISION Flex Link (DAKO, Carpinteria, CA) following the
manufacturer’s instructions. All staining steps were done on the
DAKO Autostainer Plus. A similar protocol was used to stain for
PARK-7 and NP using their respective primary antibodies (both
monoclonal from Abcam, Cambridge, MA).
Evaluation of PARK-7, aSyn and NP Expression
Immunohistochemical staining was independently evaluated by
2 observers. Staining was scored for extent and intensity. A total
score was derived by adding the extent and intensity scores. The
extent score represents the estimated percentage of ductal
epithelial cells staining positively. The following describes the
scores corresponding to various percentages of positively stained
ductal epithelial cells: 0, 0%; 1, 1–15%; 2, 16–50%; 3, 51 to 75%;
4, 76 to 100%. The intensity score represents the average intensity
of all positive cells such that: score of 0 is considered negative; 1 for
weak; 2 for intermediate or moderate and 3 for strong staining
intensity. A total staining score was defined as the sum of the
intensity and proportion score. Positive staining was defined to be
a total or cumulative score greater than 5.
LC-MS/MS analysis of metabolites regulated by NP
Sample preparation: An aliquot of 150 mL of serum was
deproteinized using AmiconH Ultra filter (Millipore) and 100 mlo f
the filtrate was spiked with 20 mL of the thymine-D4 (0.01 mM,
labeled internal standard). The sample was then transferred in to
an auto sampler vial, dried at 45uC in a SpeedVac evaporator
(Genevac, NY), reconstituted in to 50 mL water:acetonitrile (98:2)
mixture containing 0.1% formic acid and analyzed using Multiple
Reaction Monitoring (MRM) on an Agilent 6410 triple quadruple
mass spectrometer.
Multiple Reaction Monitoring (MRM)-based-evaluation of
levels of NP-regulated metabolites
MRM for the metabolites was performed using an Agilent triple
quadruple mass spectrometer equipped with an Agilent 1200 series
binary pump HPLC inlet. Chromatographic separation of
metabolites in the filtered serum was performed on a Zorbax
Eclipse (Agilent Technologies, CA) XDB-C18 column
(5064.6 mm i.d.; 1.8 mm particle size) maintained at 37uC. The
mobile phase used for the gradient-based separation was 0.1%
formic acid/0.2% acetic acid/water (v/v/v; A), and 0.1% formic
acid/0.2% acetic acid/acetonitrile (v/v/v; B). The initial gradient
condition of 2% of B was maintained until first 6 minutes.
Following this, the gradient was developed for a total of 6 minutes
as follows: 2% B to 30% B and then to 30% B to 90% B, each for
0.5 minutes interval followed by a organic spike from 90% B to
95% B for an additional 5 minutes. The flow rate throughout the
separation was maintained at 0.2 mL/min. The samples were kept
at 4uC throughout the analysis and the injection volume was kept
at 5 mL. The mass spectrometer was operated in the electrospray
positive ionization mode with a capillary voltage of 3000 V, a
collision gas flow rate of 10 L/min and a nebulizer gas flow rate of
35 L/min. The temperature of nebulizer gas was maintained at
350uC. Nitrogen was used as the collision gas at a collision cell
pressure of 2.39610
25 Torr. The details of the MRM transitions
for the metabolites examined are given in Table S5.
Statistical analysis of MRM data
Two-sided student t-tests were used to determine relative
differences between PDAC and benign samples, using the log
ratios of metabolite versus thymine-D4 (internal standard, IS);
FDR was estimated as V/R, where V is the expected number of
false positives ([nominal p-value]*[number of comparisons made])
and R is the number of both true and false positives.
Supporting Information
Figure S1 Heat map representation of pancreatic juice
proteome. A total of 431 proteins were detected in 25 pancreatic
juice samples (7 benign, 2 carcinoma in situ (CIS), and 16
pancreatic cancer (PDAC). Columns represent samples and rows
refer to proteins. Shades of yellow represents elevation of a protein
and shades of blue indicates decrease of a protein relative to the
median expression value for all the proteins identified.
(TIF)
Figure S2 Immunostaining for PARK-7 or DJ-1 in
pancreatic tissues. A) Representative photomicrograph show-
ing immunostaining of PARK-7 or DJ-1 in benign pancreas B)
same as A but in PDAC, C) quantification of TMA staining for
PARK-7 in benign (n=28) and PDAC samples (n=76).
(TIF)
Figure S3 Immunostaining of aSyn in pancreatic tis-
sues. Representative photomicrographs of aSyn staining in a
benign (panel A–C) and in PDAC specimens (panels D–F).
(TIF)
Figure S4 Representative photomicrographs of the
TMA showing aggregated staining pattern for aSyn in
PDAC (panels A and B).
(TIF)
Figure S5 Comparison of NP expression in PDAC and
other cancers. Immunoblot analysis was performed using NP
antibody on serum from PDAC patients (n=25) and other cancers
(n=11). The latter included serum from breast (n=2), lung (n=4),
colon (n=2), kidney (n=2) and duodenal (n=1) tumors. In each
case the intensities of upper 32 KDa NP immunoreactive protein
and 55 KDa IgM (control) were measured using Image-X and the
ratio of NP to IgM was derived and plotted on Y-axis.
(TIF)
Table S1 Spearman’s correlation between TMA scores
and clinical variables. The extent of staining for both alpha
synuclein and nucleoside phosphorylase were positively correlated
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correlated with presence of metastasis. On the contrary, intensity
of alpha synuclein and nucleoside phosphorylase staining were
positively correlated with existence of metastasis and negatively
correlated with T-stage and perineural invasion. ASN: alpha
synuclein, NP: nucleoside phosphorylase, T: T-stage, N: Lymph
node status, M: existence of metastasis, Ext: extent of staining, Int:
intensity of staining.
(PDF)
Table S2 Clinical information for pancreatic juice
specimens used for mass-spectrometry-based protein
profiling. For columns labeled Node, Metastatic and Margin, a
value of 0 indicates absence and 1 indicates presence. Node refers
to lymph node metastasis. Evaluation of the Margins were done
post-resection of the tumor.
(PDF)
Table S3 Clinical information of tissues used to con-
struct Tissue Microarrays. Detailed clinical information was
not available for 4 PDAC specimens.
(PDF)
Table S4 Clinical information of the serum samples
used to evaluate NP expression and levels of NP-
regulated metabolites. Asterisk indicate duplicate samples
from the same patient.
(PDF)
Table S5 List of MRM-transitions used to examine the
levels of 7 NP-regulated metabolites in serum. Thymine-
D4 is an isotopically-labeled internal standard which was spiked in
equimolar amounts into the serum prior to extraction of
metabolites.
(PDF)
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